Cytomegalovirus and Glioblastoma: TABLE

Challenging cytomegalovirus data in glioblastoma.

Dear Editor, The trial of add-on valganciclovir in glioblastoma therapy published by the authors did not provide evidence for activity of the anti-cytomegalovirus therapy. 1 Why do the presented data 2 differ substantially from the data of the controlled trial? The authors created a long-term benefiting subgroup of patients mixed from both arms of the original trial and patients from compassion...

Immunological targeting of cytomegalovirus for glioblastoma therapy

Human cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent from the normal brain, making CMV antigens potentially ideal immunological anti-GBM targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are capable of recognizing and killing autologous GBM tumor cells. This data supports CMV antigen-directed immunotherapies against GBM.

Is cytomegalovirus a therapeutic target in glioblastoma?

Several investigators have now demonstrated the expression of genes unique to cytomegalovirus (CMV) in malignant gliomas. Many of these genes promote oncogenesis, alter tumor microenvironment, and serve as immunologic targets. Is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes? Can CMV serve as a target for therapeutic interve...

The legend of cytomegalovirus and glioblastoma lives on.

Consensus on the role of human cytomegalovirus in glioblastoma.

The human cytomegalovirus (HCMV) and glioma symposium was convened on April 17, 2011 in Washington, DC, and was attended by oncologists and virologists involved in studying the relationship between HCMV and gliomas. The purpose of the meeting was to reach a consensus on the role of HCMV in the pathology of gliomas and to clarify directions for future research. First, the group summarized data t...